Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) [Phase 1]
A Phase 1 clinical trial evaluating STX-0712 in patients with advanced hematologic malignancies is currently recruiting. The study includes …
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT [Phase 1]
This is an active Phase 1 clinical trial evaluating Gamma Delta T-cell Infusion for Acute Myeloid Leukemia at high risk of relapse after all…
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation [Phase 1]
Phase 1 clinical trial evaluating the IDH1 inhibitor olutasidenib in a single-plus combo therapy for IDH1-mutant acute myeloid leukemia afte…
-
FDA approval · 2026-02-06FDA Approved: IDAMYCIN PFS — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for IDAMYCIN PFS (idarubicin hydrochloride) from Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) [Phase 2]
Phase 2 trial evaluating alternating regimens of cladribine plus low-dose cytarabine with decitabine for acute myeloid leukemia or high-risk…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-02-05EMA Authorised: Vanflyta (quizartinib dihydrochloride) — Daiichi Sankyo Europe GmbH
The European Medicines Agency authorised Vanflyta (quizartinib dihydrochloride) from Daiichi Sankyo Europe GmbH for the treatment of acute m…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax [Phase 1, Phase 2]
A multi-site Phase 1/2 trial evaluating a three-drug regimen (tagraxofusp, azacitidine, and venetoclax) for measurable residual disease in a…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis [Phase 2]
Phase 2 clinical trial evaluating reduced-dose post-transplant cyclophosphamide as GVHD prophylaxis in HLA-mismatched unrelated donor periph…
-
CLINICAL_TRIALS trial_result · 2026-02-04Clinical Trial Update: Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia [Phase 2]
Phase 2 trial evaluating cladribine plus homoharringtonine and cytarabine (CHA) for de novo acute myeloid leukemia has completed, with the u…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission [Phase 2]
This clinical trial update outlines a Phase 2 study evaluating a DC/AML fusion cell vaccine versus observation in AML patients who achieved …
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML [Phase 2]
A Phase 2 clinical trial is evaluating alternating VA and low-dose CHA regimens for unfit, newly diagnosed acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2026-02-04Clinical Trial Update: Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML [Phase 2]
Phase 2 trial evaluating gilteritinib plus VA (venetoclax and azacitidine) followed by consolidation chemotherapy in newly diagnosed FLT3-IT…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS [Phase 1]
Phase 1 study evaluating APL-4098 alone and in combination for adults with acute myeloid leukemia or myelodysplastic syndromes; currently re…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients [NA]
This clinical trial update reports ongoing recruitment for a study investigating epigenetic markers in elderly patients with acute myeloid l…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Effect of Hypnosis and Virtual Reality on Anxiety During Treatment for Acute Myeloid Leukemia [NA]
This clinical trial aims to assess whether hypnosis combined with virtual reality can reduce anxiety in patients undergoing treatment for ac…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia [Phase 1]
A Phase 1 trial evaluating dalbavancin-based prophylaxis in children and adolescents with high-risk leukemia; the study is currently recruit…
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
A clinical trial evaluating toxicity determinants and responses to azacitidine and venetoclax in acute myeloid leukemia. It is currently rec…
-
CLINICAL_TRIALS trial_result · 2026-01-30Clinical Trial Update: Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia [Phase 1]
Phase I trial evaluating AZD1775 in combination with belinostat for relapsed or refractory myeloid malignancies or untreated acute myeloid l…
-
CLINICAL_TRIALS trial_result · 2026-01-30Clinical Trial Update: Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome
A completed clinical trial evaluating mesenchymal stem cells in the tumor microenvironment of NPM1-mutated low-risk acute myeloid leukemia a…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT [Phase 1]
A Phase I clinical trial for patients with advanced hematologic malignancies undergoing allogeneic hematopoietic cell transplantation is cur…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer [Phase 2]
Phase 2 clinical trial evaluating FLAG-Ida chemotherapy followed by reduced-intensity total body irradiation and donor hematopoietic cell tr…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT [Phase 2]
Phase 2 clinical trial comparing two reduced-intensity conditioning regimens—clofarabine vs. fludarabine—in adults with acute myeloid leukem…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Expanded Access to Venetoclax
Expanded access to venetoclax is being offered for multiple hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, A…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH [Phase 1]
Phase 1 study of HMPL-306 in advanced hematologic cancers with IDH mutation has been terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms [Phase 1]
Phase 1 safety, tolerability and preliminary efficacy study of NC525 in adults with advanced myeloid neoplasms has been terminated and resul…